N-tert-butyl-4-isobutylbenzenesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-tert-butyl-4-isobutylbenzenesulfonamide
• 英文别名: N-tert-Butyl-4-iso-butylbenzenesulfonamide；N-tert-butyl-4-(2-methylpropyl)benzenesulfonamide
• 化学式: C₁₄H₂₃NO₂S
• mdl: MFCD05086529
• 分子量: 269.408
• InChiKey: QQYXOMOWIWCUAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-tert-butyl-4-isobutylbenzenesulfonamide 在 正丁基锂 、 硼酸三异丙酯 、 盐酸 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 生成 (2-(N-(tert-butyl)sulfamoyl)-5-isobutylphenyl)boronic acid
  参考文献：
  名称：

  Selective angiotensin II AT2 receptor agonists: Benzamide structure–activity relationships

  摘要：

  In the investigation of the structure-activity relationship of nonpeptide AT(2) receptor agonists, a series of substituted benzamide analogues of the selective nonpeptide AT(2) receptor agonist M024 have been synthesised. In a second series, the biphenyl scaffold was compared to the thienylphenyl scaffold and the impact of the isobutyl substituent and its position on AT(1)/AT(2) receptor selectivity was also investigated. Both series included several compounds with high af. nity and selectivity for the AT(2) receptor. Three of the compounds were also proven to function as agonists at the AT(2) receptor, as deduced from a neurite outgrowth assay, conducted in NG108-15 cells. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.05.066
• 作为产物：
  描述：

  异丁基苯 在 氯磺酸 作用下， 以 二氯甲烷 、 氯仿 为溶剂， 反应 8.75h， 生成 N-tert-butyl-4-isobutylbenzenesulfonamide
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates

  摘要：

  A series of novel 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives were designed and synthesized to develop new angiotensin II subtype 2 (AT(2)) receptor agonists as novel antihypertensive candidates. It was found that 14f (IC50 = 0.4 nM) and 15e (IC50 = 5.0 nM) displayed potent AT(2) receptor affinity and selectivity in binding assays. Biological evaluation in vivo suggested that 14f is obviously superior to that of reference drug losartan in RHRs, and meanwhile, 14f has no significant impact on heart rate. The interesting activities of these compounds may make them promising candidates as antihypertensive agents. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.10.017

文献信息

• Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT₂ Receptor Ligands
  作者：Charlotta Wallinder、Christian Sköld、Milad Botros、Marie-Odile Guimond、Mathias Hallberg、Nicole Gallo-Payet、Anders Karlén、Mathias Alterman

  DOI：10.1021/ml500427r

  日期：2015.2.12

  Migration of the methylene imidazole side chain in the first reported selective drug-like AT2 receptor agonist C21/M024 (1) delivered the AT2 receptor antagonist C38/M132 (2). We now report that the AT2 receptor antagonist compound 4, a biphenyl derivative that is structurally related to 2, is transformed to the agonist 6 by migration of the isobutyl group. The importance of the relative position of

  亚甲基咪唑侧链在第一个报道的选择性药物样AT 2受体激动剂C21 / M024（1）中的迁移提供了AT 2受体拮抗剂C38 / M132（2）。现在我们报告AT 2受体拮抗剂化合物4，一种与2结构相关的联苯衍生物，通过异丁基的迁移转化为激动剂6。本文突出了亚甲基咪唑和异丁基取代基的相对位置的重要性。
• Tricyclic compounds useful as angiotensin II agonists
  申请人：——

  公开号：US20040167176A1

  公开（公告）日：2004-08-26

  There is provided compounds of formula (I), wherein X 1 , X 2 , X 3 , Y 4 , Y 1 , Y 2 , Y 3 , Y 4 , Z 1 , Z 2 , R 4 and R 5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.

  提供了公式(I)的化合物，其中X1、X2、X3、Y1、Y2、Y3、Y4、Z1、Z2、R4和R5在说明中给出了它们的含义，以及其药学上可接受的盐。这些化合物可用作AT2受体的选择性激动剂，因此特别适用于治疗胃肠道疾病（如消化不良、肠易激综合征和多器官衰竭等）和心血管疾病。
• Tricyclic Compounds Useful as Angiotensin II Agonists
  申请人：ALTERMAN Mathias

  公开号：US20090326026A1

  公开（公告）日：2009-12-31

  There is provided compounds of formula (I), wherein X 1 , X 2 , X 3 , Y 4 , Y 1 , Y 2 , Y 3 , Y 4 , Z 1 , Z 2 , R 4 and R 5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.

  提供公式（I）的化合物，其中X1、X2、X3、Y1、Y2、Y3、Y4、Z1、Z2、R4和R5的含义如描述中所述，并且其药学上可接受的盐，这些化合物在AT2受体的选择性激动剂中有用，因此特别适用于治疗胃肠道疾病，如消化不良、肠易激综合征和多器官功能障碍，以及心血管疾病。
• [EN] SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS<br/>[FR] LIGANDS SÉLECTIFS DU RÉCEPTEUR DE L'ANGIOTENSINE II
  申请人：VICORE PHARMA AB

  公开号：WO2022200785A1

  公开（公告）日：2022-09-29

  There is provided pharmaceutical compounds of formula I, wherein R1, R2, R3, R4, R6, X, Y, Z, Y1, Y2, Y3and Y4have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.

  提供了式子I的药物化合物，其中R1、R2、R3、R4、R6、X、Y、Z、Y1、Y2、Y3和Y4的含义在说明中给出，这些化合物在治疗自身免疫和/或纤维化疾病方面有用，包括间质性肺病，如特发性肺纤维化和结节病。
• 作为AT2R激动剂的杂环化合物
  申请人：武汉人福创新药物研发中心有限公司

  公开号：CN116891463A

  公开（公告）日：2023-10-17

  本发明提供了式I所示杂环化合物、其互变异构体、立体异构体、水合物、溶剂化物、药学上可接受的盐或前药；所述杂环化合物对与AT2受体相关疾病有治疗作用，#imgabs0#